Greenwich LifeSciences, Inc. (NASDAQ:GLSI - Get Free Report) shares traded down 5.8% on Friday . The stock traded as low as $11.55 and last traded at $11.59. 154,544 shares changed hands during mid-day trading, an increase of 233% from the average session volume of 46,360 shares. The stock had previously closed at $12.30.
Analysts Set New Price Targets
Separately, HC Wainwright upped their price objective on Greenwich LifeSciences from $38.00 to $39.00 and gave the stock a "buy" rating in a report on Monday, April 21st.
Check Out Our Latest Research Report on Greenwich LifeSciences
Greenwich LifeSciences Stock Performance
The business's 50 day moving average is $9.77 and its 200 day moving average is $10.75. The stock has a market cap of $148.94 million, a price-to-earnings ratio of -8.84 and a beta of 1.63.
Greenwich LifeSciences (NASDAQ:GLSI - Get Free Report) last released its earnings results on Tuesday, May 20th. The company reported ($0.25) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.24) by ($0.01). Research analysts expect that Greenwich LifeSciences, Inc. will post -0.8 earnings per share for the current year.
Insider Buying and Selling at Greenwich LifeSciences
In other news, CEO Snehal Patel purchased 3,600 shares of Greenwich LifeSciences stock in a transaction on Friday, April 25th. The shares were purchased at an average cost of $9.88 per share, for a total transaction of $35,568.00. Following the completion of the transaction, the chief executive officer directly owned 5,570,602 shares in the company, valued at approximately $55,037,547.76. This represents a 0.06% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Company insiders own 51.67% of the company's stock.
Institutional Investors Weigh In On Greenwich LifeSciences
A number of institutional investors and hedge funds have recently modified their holdings of the business. Rhumbline Advisers raised its stake in shares of Greenwich LifeSciences by 48.7% during the first quarter. Rhumbline Advisers now owns 9,673 shares of the company's stock worth $92,000 after buying an additional 3,168 shares during the last quarter. Strs Ohio bought a new stake in Greenwich LifeSciences in the first quarter valued at approximately $177,000. HighTower Advisors LLC bought a new stake in Greenwich LifeSciences in the first quarter valued at approximately $147,000. Charles Schwab Investment Management Inc. increased its stake in Greenwich LifeSciences by 15.5% in the first quarter. Charles Schwab Investment Management Inc. now owns 19,007 shares of the company's stock valued at $181,000 after purchasing an additional 2,552 shares in the last quarter. Finally, GAMMA Investing LLC bought a new stake in Greenwich LifeSciences in the first quarter valued at approximately $126,000. 4.16% of the stock is owned by institutional investors.
Greenwich LifeSciences Company Profile
(
Get Free Report)
Greenwich LifeSciences, Inc, a clinical-stage biopharmaceutical company, develops novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers. Its lead product candidate is GP2, an immunotherapy, which is in Phase III clinical trial to prevent breast cancer recurrences in patients who have previously undergone surgery.
Read More
Before you consider Greenwich LifeSciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Greenwich LifeSciences wasn't on the list.
While Greenwich LifeSciences currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Unlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.